Aeterna Zentaris will present at BIO CEO & Investor Conference 2022

Enter Wall Street with StreetInsider Premium. Claim your one week free trial here.

CHARLESTON, South Carolina, Feb. 07 2022 (GLOBE NEWSWIRE) — Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products, today announced that Dr. Klaus Paulini, Chief Executive Officer of Aeterna Zentaris, will present at the BIO CEO & Investor Conference to be held in New York, NY and virtually, February 14-17, 2022.

In addition to the presentation, management will be available to participate in one-on-one virtual meetings with qualified members of the investment community who are registered to attend the conference. For more information about the conference, please visit the conference website.

A video webcast of the presentation will be available upon request to those registered for the event.

About Aeterna Zentaris Inc.

Aeterna Zentaris is a specialty biopharmaceutical company that develops and markets a diverse portfolio of pharmaceutical and diagnostic products focused on areas of high unmet medical need. The company’s lead product, macimorelin (Macrilen™), is the first and only oral test approved by the US FDA and the European Commission indicated for the diagnosis of adult growth hormone deficiency (AGHD). The Company is building on the clinical success and compelling safety profile of macimorelin to develop it for the diagnosis of childhood growth hormone deficiency (CGHD), an area of ​​significant unmet need, in collaboration with Novo Nordisk.

Aeterna Zentaris is dedicated to the development of therapeutic assets and has recently taken steps to establish a growing preclinical pipeline to potentially address unmet medical needs in a number of indications, including neuromyelitis optica spectrum disorder ( NMOSD), Parkinson’s disease (PD), hypoparathyroidism and amyotrophic lateral sclerosis (ALS; Lou Gehrig’s disease). Additionally, the Company is developing an oral prophylactic bacterial vaccine against SARS-CoV-2 (COVID-19) and Chlamydia trachomatis.

For more information, visit and connect with the company on Twitter, LinkedIn and Facebook.

Investor contacts:

jenene thomas
T (US): +1 (833) 475-8247
Email: [email protected]

Comments are closed.